Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Procopio

Showing results (181-190 of 289) with videos related to

Pageof 29
Sort By:
Cancer Treatment and Research Communications|November 3, 2019
Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective studySebastiano Buti, Melissa Bersanelli, Alessandro Viansone, et al.
Prostate Cancer and Prostatic Diseases|May 3, 2025
Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II BONENZA trialAlberto Dalla Volta, Francesca Valcamonico, Andrea Zivi, et al.
BJU International|February 6, 2021
Outcomes of systemic targeted therapy in recurrent renal cell carcinoma treated with adjuvant sunitinibGuillermo de Velasco, Álvaro Ruiz-Granados, Oscar Reig, et al.
European Urology Oncology|September 23, 2019
Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT StudyGiuseppe Procopio, Giulia Apollonio, Francesco Cognetti, et al.
Clinical Genitourinary Cancer|December 31, 2024
A Prospective Non-interventional Real-World Study of cabozantinib in Pretreated Patients With Advanced Renal Cell Carcinoma Refractory to Vascular Endothelial Growth Factor-Targeted Therapy (CASSIOPE)Michael Staehler, Umberto Basso, Jean-Christophe Eymard, et al.
Plos One|April 12, 2016
Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective AnalysisPaolo Grassi, Ludovic Doucet, Palma Giglione, et al.
Plos One|July 7, 2018
Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in ItalyMaria Giuseppa Vitale, Sarah Scagliarini, Luca Galli, et al.
Targeted Oncology|January 7, 2015
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapyMatteo Santoni, Sebastiano Buti, Alessandro Conti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 11, 2019
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with NivolumabUgo De Giorgi, Giuseppe Procopio, Diana Giannarelli, et al.
JMIR Cancer|January 22, 2025
Patient Voices: Multimethod Study on the Feasibility of Implementing Electronic Patient-Reported Outcome Measures in a Comprehensive Cancer CenterCinzia Brunelli, Sara Alfieri, Emanuela Zito, et al.
Pageof 29

Showing results (181-190 of 289) with videos related to

Sort By:
Pageof 29
Cancer Treatment and Research Communications|November 3, 2019
Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective studySebastiano Buti, Melissa Bersanelli, Alessandro Viansone, et al.
Prostate Cancer and Prostatic Diseases|May 3, 2025
Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II BONENZA trialAlberto Dalla Volta, Francesca Valcamonico, Andrea Zivi, et al.
BJU International|February 6, 2021
Outcomes of systemic targeted therapy in recurrent renal cell carcinoma treated with adjuvant sunitinibGuillermo de Velasco, Álvaro Ruiz-Granados, Oscar Reig, et al.
European Urology Oncology|September 23, 2019
Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT StudyGiuseppe Procopio, Giulia Apollonio, Francesco Cognetti, et al.
Clinical Genitourinary Cancer|December 31, 2024
A Prospective Non-interventional Real-World Study of cabozantinib in Pretreated Patients With Advanced Renal Cell Carcinoma Refractory to Vascular Endothelial Growth Factor-Targeted Therapy (CASSIOPE)Michael Staehler, Umberto Basso, Jean-Christophe Eymard, et al.
Plos One|April 12, 2016
Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective AnalysisPaolo Grassi, Ludovic Doucet, Palma Giglione, et al.
Plos One|July 7, 2018
Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in ItalyMaria Giuseppa Vitale, Sarah Scagliarini, Luca Galli, et al.
Targeted Oncology|January 7, 2015
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapyMatteo Santoni, Sebastiano Buti, Alessandro Conti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 11, 2019
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with NivolumabUgo De Giorgi, Giuseppe Procopio, Diana Giannarelli, et al.
JMIR Cancer|January 22, 2025
Patient Voices: Multimethod Study on the Feasibility of Implementing Electronic Patient-Reported Outcome Measures in a Comprehensive Cancer CenterCinzia Brunelli, Sara Alfieri, Emanuela Zito, et al.
Pageof 29